Analytics will be one of the main growth areas in software next year. As more organizations realize the power of their internal, machine-generated and customer data, they are increasingly turning to business intelligence/analytics software, particularly solutions that visualize information in an easy-to-understand format that shows key trends and insights. The… Read More
Archive
Filter
We are in uncharted waters and risk is extremely high for the financial markets at the moment. Investors in biotech and beyond will have a lot to consider in the next few days. Read More
There was a time not that long age – actually, when I started driving as a teenager in the 1970s – that an automobile was about as low tech as something could get. I recall removing the back doors of my Ford Maverick with nothing more than a ratchet tool… Read More
The “two-tier” stock market we have been expecting for the past year is finally here, and along with it comes heightened volatility now that companies are competing for a more finite amount of investor capital. In simplest terms that means good companies benefit at the expense of bad ones, amplifying… Read More
While some tech companies, like Hewlett Packard, are splitting up to move forward, others are consolidating via acquisitions that accelerate the implementation of their strategic plans. In this week’s issue we’ll look at two such deals that affect our portfolios, one of which we discussed briefly last week (EMC) and… Read More
[from today’s edition of Smart Tech 50 Weekly Movers]Dyax Corp. (DYAX) received a $5.9 billion dollar buyout offer from Shire Pharmaceuticals. The stock, early on Monday morning (11/2/15) was trading above $36 per share, a nearly 33% premium over the 10/30/15 closing price. We recommend sale of the shares for… Read More
[from today’s edition of Smart Tech 50 Weekly Movers]Dyax Corp. (DYAX) received a $5.9 billion dollar buyout offer from Shire Pharmaceuticals. The stock, early on Monday morning (11/2/15) was trading above $36 per share, a nearly 33% premium over the 10/30/15 closing price. We recommend sale of the shares for… Read More
As described in today’s edition of Smart Tech 50 Weekly Movers, we are selling EMC (EMC) and CA Technologies (CA) out of the STI Investments Portfolio due to their limited upside potential, and changing Microsoft (MSFT) to a hold given its recent price surge. Read More
As described in today’s edition of Smart Tech 50 Weekly Movers, we are selling EMC (EMC) and CA Technologies (CA) out of the STI Investments Portfolio due to their limited upside potential, and changing Microsoft (MSFT) to a hold given its recent price surge. Read More
[from today’s edition of Smart Tech 50 Weekly Movers]Celldex Therapeutics (CLDX) is almost an EBIS stock. The company is working on a vaccine for aggressive brain cancers. It has plenty of money on its balance sheet but is high risk and has not been able to make money consistently. Read More